8-K: Exagen Inc. Announces Strong Q4 and Full-Year 2024 Results, Driven by Revenue Growth and Improved Profitability

Exagen Inc. reports record full-year revenue and improved profitability metrics for 2024, driven by increased average selling prices and operational efficiencies.

Summary

• Exagen Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company achieved record total revenue of $55.6 million for the full year, driven by continued expansion of the AVISE CTD average selling price (ASP).
• The AVISE CTD trailing twelve-month ASP increased to $411, a $75 increase per test.
• Gross margin improved to 62.1% in the fourth quarter and 59.5% for the full year.
• Net loss improved by $1.8 million in the fourth quarter and over $8 million for the full year compared to 2023.
• Adjusted EBITDA loss improved by $1.3 million in the fourth quarter and nearly $7 million for the full year compared to 2023.
• The company ended 2024 with $22.2 million in cash and restricted cash.
• Exagen expects total revenue of at least $14.5 million for the first quarter of 2025.
• The company anticipates being on track to deliver positive adjusted EBITDA in the fourth quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, improved profitability metrics, and promising future guidance. The management's comments are optimistic, and the company seems to be on track to achieve its goals.

Positives

• Record full-year revenue of $55.6 million indicates strong market demand for Exagen's testing services.
• The increase in AVISE CTD ASP to $411 demonstrates the company's ability to command higher prices for its tests.
• Improved gross margins suggest better cost management and operational efficiency.
• Significant reduction in net loss and adjusted EBITDA loss indicates progress towards profitability.
• The company's cash position of $22.2 million provides a financial cushion for future investments and operations.
• The launch of new SLE and RA biomarker assays expands Exagen's product offerings and market reach.
• The company expects to be on track to deliver positive adjusted EBITDA in the fourth quarter of 2025.

Negatives

• The company still reported a net loss of $15.115 million for the full year 2024, despite improvements.
• Adjusted EBITDA remains negative at $(10.149) million for the full year 2024, although it has improved from the previous year.

Risks

• Delays in reimbursement and coverage decisions from Medicare and third-party payors could impact revenue.
• Failure to maintain market acceptance of testing products among rheumatologists, patients, and payors could hinder growth.
• Inability to obtain and maintain intellectual property protection could lead to increased competition.
• Regulatory developments affecting Exagen's business could create compliance challenges.
• The company's future performance is subject to risks and uncertainties outlined in its SEC filings.

Future Outlook

Exagen expects total revenue of at least $14.5 million for the first quarter of 2025 and anticipates being on track to deliver positive adjusted EBITDA in the fourth quarter of 2025. The company plans to provide full-year 2025 financial outlook with the release of its first quarter 2025 results.

Management Comments

• The execution of our operational turnaround continued in earnest during 2024, which is reflected in our transformative financial results and is a testament to the strength of our team and strategy, said John Aballi, President and CEO.
• We have continued to grow profitable revenue and expand gross margins while significantly reducing operating expenses and cash burn.
• Additionally, the successful launch of our new AVISE CTD biomarkers this past January is a significant milestone in our commitment to improving patient care.
• With these accomplishments, Exagen is better positioned for success, and I am excited about the momentum we carry into 2025 as we drive towards profitability.

Industry Context

Exagen operates in the autoimmune testing market, which is characterized by increasing demand for diagnostic tools that can aid in the early and accurate diagnosis of autoimmune diseases. The company's focus on innovative biomarkers and personalized medicine aligns with broader trends in the healthcare industry.

Comparison to Industry Standards

• It's difficult to provide a direct comparison to industry standards without knowing the specific peer group Exagen benchmarks against.
• However, companies like Myriad Genetics and Quest Diagnostics also operate in the diagnostics space.
• Exagen's focus on autoimmune diseases differentiates it from these broader diagnostic companies.
• The ASP of $411 for AVISE CTD is a key metric to compare against similar specialized diagnostic tests offered by competitors.
• The improvement in EBITDA and net loss suggests Exagen is making progress towards industry-standard profitability levels.

Stakeholder Impact

• Shareholders will likely react positively to the improved financial performance and future outlook.
• Employees may be motivated by the company's progress and potential for future success.
• Customers (rheumatologists and patients) may benefit from the company's innovative testing solutions.
• Suppliers and creditors may view the company as a more stable and reliable partner.

Next Steps

• The company will hold a conference call on March 11, 2025, to discuss the results.
• Exagen expects to provide its full-year 2025 financial outlook in connection with the release of its first quarter 2025 financial results.
• The company will file its Annual Report on Form 10-K for the year ended December 31, 2024, on or before March 14, 2025.

Key Dates